期刊文献+

阿托伐他汀对高血压脑出血急性期患者C-反应蛋白的影响 被引量:3

下载PDF
导出
摘要 目的探讨阿托伐他汀对高血压脑出血急性期患者CRP的影响。方法 80例高血压脑出血急性期患者随机分为治疗组和对照组各40例,均给予常规治疗,治疗组加用阿托伐他汀钙。结果两组入院后血清CRP水平呈下降趋势,治疗组从治疗4d起而对照组从治疗7d起血清CRP水平较入院当日下降显著(P<0.05),治疗4、7、10、14d治疗组血清CRP水平显著低于对照组(P<0.05)。两组入院后NIHSS评分呈下降趋势(P<0.05),治疗后治疗组NIHSS评分显著低于对照组(P<0.05)。血清CRP与NIHSS评分呈正相关(r=0.56,P<0.05)。结论结论:阿托伐他汀用于治疗高血压患者急性脑出血,能有效降低CRP水平,通过抑制炎症反应对神经系统的损害发挥脑保护作用。
作者 辛军
出处 《海峡药学》 2012年第3期97-98,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献5

二级参考文献43

  • 1于艳秋,张兰.阿托伐他汀治疗老年脑梗死患者炎症反应的临床疗效[J].广东医学,2005,26(12):1726-1727. 被引量:7
  • 2Ribo M, Grotta JC. Latest advances in intracerebral hemorrhage. Curr Neurol Neurosci Rep, 2006, 6 (1) : 17-22. 被引量:1
  • 3Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol, 2005, 4(10) : 662-672. 被引量:1
  • 4Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intraeerebral haemorrhage. Lancet Neurol, 2006, 5 ( 1 ) : 53 -63. 被引量:1
  • 5Joieea SL, Mydeena F, Couraud PO, et al. Modulation of blood-brain barrier permeability by neutrophils: in vitro and in vivo studies. Brain Res, 2009, 1298 : 13-23. 被引量:1
  • 6Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurological Research, 2005, 27 (3) : 268-297. 被引量:1
  • 7Gong C, Hoff JT, Keep RF. Acute inflammatory reaction following experimental intracerebral hemorrhage in rat. Brain Res, 2000, 871 ( 1 ) : 57-65. 被引量:1
  • 8Peeling J, Yan HJ, Corbett D, et al. Effect of FK-506 on inflammation and behavioral outcome following intracerebral hemorrhage in rat. Exp Neurol, 2001, 167 (2) : 341- 347. 被引量:1
  • 9Wang J, Tsirka SE. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain, 2005, 128(Pt 7) : 1622-1633. 被引量:1
  • 10Mackenzie JM, Clayton JA. Early cellular events in the penumbra of human spontaneous intracerebral hemorrhage. J Stroke and Cerebrovas Dis, 1999 , 8( 1 ) : 1-8. 被引量:1

共引文献83

同被引文献34

  • 1肖玉梅,杨景宁,蒙应东.阿托伐他汀和辛伐他汀对降脂及消退颈动脉斑块疗效的对比研究[J].广东医学院学报,2006,24(1):5-7. 被引量:6
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5224
  • 3Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovostatin, and fluvasta- tin in patients with hypercholesterolemia (the CURVES study) [ J ]. Am J Cardiol, 1998, 81 (5) : 582 -587. 被引量:1
  • 4Jones PH, Mckenney JM, Karalis DG, et al. Comparison of the effica- cy and safety ofatorvastatin initiated at different starting doses in patients withdyslipidemia [J]. Am Heart J, 2005, 149 (1): 1-8. 被引量:1
  • 5Strandberg TE, Vanhanen H, Tikkanen MJ, et al. Effect of statins on C- reactive protein in patients with coronary heart disease [ J ]. Lan- cet, 1999, 353 (9147): 118-119. 被引量:1
  • 6Hilgendorff A, Muth H, Parviz B, et al. Statins differ in their ability to block NF- KappaB activation in human blood monocytes [J]. Int J Clin Pharmacol Ther, 2003, 41 (9) : 397 -401. 被引量:1
  • 7Nissen SE, Tuzeu EM, Sehoenhagen P, et al. Effect of intensive com- parewith moderate lipid - lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial [J]. JAMA, 2004, 291 (9): 1071-1080. 被引量:1
  • 8Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke pre- vention and carotid atherosclerosis systematic review and up - to - date meta-analysis [J]. Stroke, 2004, 35 (12): 2902-2909. 被引量:1
  • 9Amaremeo P, Labreuehe J. Lipid mansgement in the prevention of stroke : review and updated meta - analysis of statins for stroke preven- tion [ J ]. The Lancet Neurology, 2009, 5 (8) : 453 - 463. 被引量:1
  • 10Heart Protection Study Collaborative Group. MRC/BHF Heart Protec- tion Study of cholesterol lowering with simvastatin in 20536 high. risk individuals: a randomised placebo - controlled trial [ J ]. Lancet, 2002, 360 (9326): 7-22. 被引量:1

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部